Cardioprotective effect of aprotinin on myocardial ischemia/reperfusion injury during cardiopulmonary bypass

Circulation Journal

Volumn 70, Issue 11, 2006, Pages 1432-1436

  Karaca, Pelin ^a   Konuralp, Cüneyt ^a,b   Enç, Yavuz ^a   Süzer, Asuman ^a   Sokullu, Onur ^a   Ayoǧlu, Umut ^a   Çiçek, Sertac ^a  

^a DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Department of Cardiovascular Surgery ^*  (Turkey)

Author keywords

Aprotinin; Cardiopulmonary bypass; Ischemia; Reperfusion injury; Troponin

Indexed keywords

APROTININ; CREATINE KINASE MB; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; HEART INDEX; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OXYGEN SATURATION; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY;

ADULT; AGED; APROTININ; CARDIOPULMONARY BYPASS; CORONARY ARTERIOSCLEROSIS; CREATINE KINASE, MB FORM; DOUBLE-BLIND METHOD; HEART; HEART ARREST, INDUCED; HUMANS; HYPOTHERMIA; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPERFUSION INJURY; SERINE PROTEINASE INHIBITORS; TROPONIN T;

EID: 33750548035     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.70.1432     Document Type: Article

References (31)

1. Forman MB, Kolodgie FD, Jenkins M, Virmani R. Myocardial infarct extention during reperfusion after coronary artery occlusion: Pathologic evidence. J Am Coll Cardiol 1993; 21: 1245-1253.
2. Entman ML, Smith CW. Postreperfusion inflammation: A model for reaction to injury after myocardial ischemia. FASEB J 1991; 5: 2029-2034.
3. Lefer AM, Spath JA. Preservation of myocardial integrity by a protease inhibitor during acute myocardial ischemia. Arch Int Pharmacodyn Ther 1974; 211: 225-236.
4. Wendel HP, Heller W, Michel J, Mayer G, Ochsenfahrt C, Graeter U, et al. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg 1995; 109: 1164-1172.
5. Bruda NL, Hurlbert BJ, Hill GE. Aprotinin reduces nitric oxide production in vitro and in vivo in a dose dependent manner. Clin Sci (Lond) 1998; 94: 505-509.
6. Asimakopoulos G, Lidington EA, Mason J, Haskard DO, Taylor KM, Landis RC. Effect of aprotinin on endothelial cell activation. J Thorac Cardiovasc Surg 2001; 122: 123-128.
7. Sunamori M, Sultan I, Suzuki A. Effect of aprotinin to improve myocardial viability in myocardial preservation followed by reperfusion. Ann Thorac Surg 1991; 52: 971-978.
8. Landis RC, Asimakopoulos G, Poullis M, Haskard DO, Taylor KM. The antithrombotic and anti-inflammatory mechanisms of action of aprotinin. Ann Thorac Surg 2001; 72: 2169-2175.
9. Asimakopoulos G. Systemic inflammation and cardiac surgery: An update. Perfusion 2001; 16: 353-360.
10. Royston D. Preventing the inflammatory response to open heart surgery: The role of aprotinin and other protease inhibitors. Int J Cardiol 1996; 53(Suppl): S11-S37.
11. Bull DA, Connors RC, Albanil A, Reid BB, Neumayer LA, Nelson R, et al. Aprotinin preserves myocardial biochemical function during cold storage through supression of tumor necrosis factor. J Thorac Cardiovasc Surg 2000; 119: 242-250.
12. Wei M, Kuukasjarv P, Laurikka J, Pehkonen E, Kaukinen S, Honkonen EL, et al. Cardioprotective effect of pump prime aprotinin in coronary artery bypass grafting. Cardiovasc Drugs Ther 2002; 16: 37-42.
13. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol 1998; 274: 577-595.
14. Akar H, Sarac A, Konuralp C, Yildiz L, Kolbakir F. Comparison of histopathologic effects of carnitine and ascorbic acid on reperfusion injury. Eur J Cardiothorac Surg 2001; 19: 500-506.
15. Birk-Sorensen L, Fuglsang J, Sorensen HB, Kerrigan CL, Petersen LC, Ravn HB, et al. Aprotinin attenuates platelet accumulation in ischaemia-reperfusion- injured porcine skeletal muscle. Blood Coagul Fibrinolysis 1999; 10: 157-165.
16. Formigli L, Manneschi LI, Nediani C, Marcelli E, Fratini G, Orlandini SZ, et al. Are macrophages involved in early myocardial reperfusion injury? Ann Thorac Surg 2001; 71: 1596-1602.
17. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol 1998; 274: R577-R595.
18. Wagner L, Avery LK, Bensinger L, Kusinitz F, Hibberd PL, Pasternack MS. Inhibition of cytotoxic T-lymphocyte-triggered apoptosis by target cell surface-coupled aprotinin. Mol Immunol 1995; 32: 853-864.
19. Poullis M, Manning R, Laffan M, Haskard DO, Taylor KM, Landis RC. The antithrombotic effect of aprotinin: Actions mediated via the protease activated receptor 1. J Thorac Cardiovasc Surg 2000; 120: 370-378.
20. Asimakopoulos G, Thompson R, Nourshargh S, Lidington EA, Mason JC, Ratnatunga CP, et al. An anti-inflammatory property of aprotinin detected at the level of leucocyte extravasation. J Thorac Cardiovasc Surg 2000; 120: 361-369.
21. Tavli M, Idiz M, Kayali R, Konuralp C, Cakatay U, Camur G, et al. Effect of aprotinin on oxidative stress after cardiopulmonary bypass. Interactive Cardio Vasc Thorac Surg 2005; 4(Suppl 1): S51.
22. Buerke M, Murohara T, Lever AM. Cardioprotective effects of as C1 esterase inhibitor in mycardial ischemia and reperfusion. Circulation 1995; 91: 393-402.
23. Hoffmeister HM, Fischer M, Kazmaier S, Heller W, Seipel L. Action of aprotinin in myocardial ischemia: An investigation using a plasma-free model. Thorac Cardiovasc Surg 1999; 47: 88-93.
24. Asimakopoulos G, Kohn A, Stefanou DC, Haskard DO, Landis RC, Taylor KM. Leucocyte integrin expression in patients undergoing cardiopulmonary bypass. Ann Thorac Surg 2000; 69: 1192-1197.
25. Khan TA, Bianchi C, Araujo E, Voisine P, Xu S, Feng J, et al. Aprotinin preserves cellular junctions and reduces myocardial edema after regional ischemia and cardioplegic arrest. Circulation 2005; 112: 196-201.
26. Konuralp C, Guner S, Cakatay U, Konuralp Z, Yapici N, Macika H, et al. Effect of partial oxygen supply on mitochondrial electron transport system during complete cardiac ischemia. J Card Surg 1999; 14: 424-434.
27. Sunamori M, Amano J, Kameda T, Okamura T, Ozeki M, Suzuki A. Additive protection of aprotinin, protease inhibitor to cold cardioplegia from ischemic myocardium. Jpn Circ J 1980; 44: 771-775.
28. Royston D, Nadel A, Dietrich W, Forrest MR, Chester AH, Marczin N, et al. Aprotinin use and adverse outcomes associated with platelet administration. Anesth Analg 2000; 90(Suppl): A19.
29. Bertinchant JP, Larue C, Pernel I, Ledermann B, Fabbro-Peray P, Beck L, et al. Release kinetics of cardiac troponin I in ischemic myocardial injury. Clin Biochem 1996; 29: 587-594.
30. Collinson PO, Hadcocks L, Foo AY, Rosalki SB, Stubbs PJ, Morgan SH, et al. Cardiac troponins in patients with renal dysfunction. Ann Clin Biochem 1998; 35: 380-386.
31. Li D, Jilal I, Keffer J. Greater frequency of increased cardiac troponin T than increased troponin I in patients with chronic renal failure. Am J Clin Pathol 1996; 106: 118-123.